StockNews.com Initiates Coverage on Cara Therapeutics (NASDAQ:CARA)
Investment analysts at StockNews.com began coverage on shares of Cara Therapeutics (NASDAQ:CARA – Get Free Report) in a research note issued to investors on Wednesday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock. Cara Therapeutics Price Performance The firm has a 50-day moving average of $15.19 and a 200-day moving average of […]
Investment analysts at StockNews.com began coverage on shares of Cara Therapeutics (NASDAQ:CARA – Get Free Report) in a research note issued to investors on Wednesday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock. Cara Therapeutics Price Performance The firm has a 50-day moving average of $15.19 and a 200-day moving average of […]
